General Information of Drug Inactive Ingredient (DIG) (ID: E00428)

DIG Name
Sodium phosphate monobasic monohydrate
Synonyms
10049-21-5; Sodium dihydrogen phosphate monohydrate; Sodium phosphate monobasic monohydrate; Monosodium phosphate monohydrate; Phosphoric acid, monosodium salt, monohydrate; UNII-593YOG76RN; MFCD00149208; Sodium Phosphate Monobasic hydrate; sodium dihydrogenphosphate monohydrate; 593YOG76RN; Phosphoric acid (sodium hydrate); monohydratemonobasicsodium phosphate; sodium;dihydrogen phosphate;hydrate; Phosphoric acid, monosodium salt, monohydrate (8CI,9CI); Sodium phosphate, monobasic monohydrate, 98%, extra pure; Sodium phosphate, monobasic monohydrate, 98+%, ACS reagent; Sodium phosphate, monobasic monohydrate, 99+%, for analysis; Sodium phosphate, monobasic monohydrate, 99.5%, for biochemistry; sodium dihydrogen phosphate hydrate; PubChem12707; Na.H2O.H2PO4; DTXSID6073994; sodium dihydrogenphosphate hydrate; CHEBI:114249; sodium dihydrogen phosphate, hydrate; 8870AF; AKOS015913977; AKOS028109193; sodium phosphate mono-basic monohydrate; monosodium mono(hydrogenphosphate) hydrate; sodium dihydrogen phosphate--water (1/1); FT-0645113; Sodium phosphate monobasic monohydrate, p.a.; Sodium dihydrogen phosphate monohydrate, Puratronic; Sodium phosphate monobasic monohydrate ACS granular; J-000147; Q27195646; Sodium phosphate monobasic monohydrate, ACS reagent, >=98%; UNII-3980JIH2SW component BBMHARZCALWXSL-UHFFFAOYSA-M; UNII-SE337SVY37 component BBMHARZCALWXSL-UHFFFAOYSA-M; Sodium phosphate monobasic monohydrate, technical grade, 90%; Sodium phosphate monobasic monohydrate, purum p.a., >=99.0% (T); Sodium phosphate monobasic monohydrate, Vetec(TM) reagent grade, 98%; Sodium phosphate monobasic monohydrate, BioXtra, for molecular biology, >=99.5% (T); Sodium phosphate monobasic monohydrate, puriss. p.a., ACS reagent, >=99.0% (T); Sodium phosphate monobasic monohydrate, BioReagent, suitable for electrophoresis, 98.0-102.0%; Sodium phosphate monobasic monohydrate, PharmaGrade, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production.
DIG Function
Buffering agent; Complexing agent
Formula
H4NaO5P
Canonical SMILES
O.OP(=O)(O)[O-].[Na+]
InChI
1S/Na.H3O4P.H2O/c;1-5(2,3)4;/h;(H3,1,2,3,4);1H2/q+1;;/p-1
InChIKey
BBMHARZCALWXSL-UHFFFAOYSA-M
Physicochemical Properties Molecular Weight 137.99 Topological Polar Surface Area 81.6
XlogP N.A. Complexity 61.9
Heavy Atom Count 7 Rotatable Bond Count 0
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5

Full List of Drug(s) Co-administrated with This DIG

5 Approved Drug(s) Co-administrated with This DIG
Drug Name Drug ID Indication Formulation Name Formulation ID
Betamethasone DMAHJEF Acute adrenal insufficiency [] Betamethasone 0.05% cream F23646
Clotrimazole DMMFCIH Cutaneous candidiasis [1F23.14] Clotrimazole eq 0.05% base cream F24431
Latanoprost DMI5OXG Ocular hypertension [9C61.01] Latanoprost 0.005% solution F24273
Regadenoson DM76VHG Radionuclide imaging [N.A.] Regadenoson 0.4mg/5ml solution F23266
Risedronate DM5FLTY Bone Paget disease [] Risedronic acid 150 mg tablet F19012
------------------
1 Clinical Trial Drug(s) Co-administrated with This DIG
Drug Name Drug ID Indication Formulation Name Formulation ID
ABT-492 DMJFD2I Bacterial infection [1A00-1C4Z] Delafloxacin Meglumine 300 mg For Injection F23417
------------------